The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice
Open accessAbstract
Recently, the European Medicines Agency approved the use of the vasopressin V2 receptor antagonist tolvaptan to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adult patients with chronic kidney disease stages 1-3 at initiation of treatment with evidence of rapidly progressing disease. In this paper, on behalf of the ERA-EDTA Working Groups of Inherited Kidney Disorders and European Renal Best Practice, we aim to provide guidance for making the decision as to which ADPKD patients to treat with tolvaptan. The present position statement includes a series of recommendations resulting in a hierarchical decision algorithm that encompasses a sequence of risk-factor assessments in a descending order of reliability. By examining the best-validated markers first, we aim to identify ADPKD patients who have documented rapid disease progression or are likely to have rapid disease progression. We believe that this procedure offers the best opportunity to select patients who are most likely to benefit from tolvaptan, thus improving the benefit-to-risk ratio and cost-effectiveness of this treatment. It is important to emphasize that the decision to initiate treatment requires the consideration of many factors besides eligibility, such as contraindications, potential adverse events, as well as patient motivation and lifestyle factors, and requires shared decision-making with the patient.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394 · cited 3×
“…which tested angiotensin-2 receptor antagonists in patients with type 2 diabetes and kidney disease [13, 14], and with the 35% reduction in decline in creatinine clearance in the study that tested angiotensin-converting enzyme inhibition in patients with type 1 diabetes and kidney disease [11].”
BackgroundInfluentialEstimating glomerular filtration rate from serum creatinine and cystatin C
Inker, L. A., Schmid, C. H., Tighiouart, H., Eckfeldt, J. H., Feldman, H. I., Greene, T., Kusek, J. W., Manzi, J., Van Lente, F., Zhang, Y. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114248 · Cited by 4,102
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citationLimitations of creatinine as a filtration marker in glomerulopathic patients
Shemesh, O., Golbetz, H., Kriss, J. P., & Myers, B. D. (1985) · Kidney International · doi:10.1038/ki.1985.205 · Cited by 1,227
Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988
Self-citationVolume Progression in Polycystic Kidney Disease
Grantham, J. J., Torres, V. E., Chapman, A. B., Guay-Woodford, L. M., Bae, K. T., King, B. F., Wetzel, L. H., Baumgarten, D. A., Kenney, P. J., Harris, P. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054341 · Cited by 807
Irazabal, M. V., Rangel, L. J., Bergstralh, E. J., Osborn, S. L., Harmon, A. J., Sundsbak, J. L., Bae, K. T., Chapman, A. B., Grantham, J. J., Mrug, M., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101138 · Cited by 625
Levey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Chapman, A. B., Devuyst, O., Eckardt, K.-U., Gansevoort, R. T., Harris, T., Horie, S., Kasiske, B. L., Odland, D., Pei, Y., Perrone, R. D., et al. (2015) · Kidney International · doi:10.1038/ki.2015.59 · Cited by 611
Self-citationAutosomal Dominant Polycystic Kidney Disease
Grantham, J. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0804458 · Cited by 543
Type of PKD1 Mutation Influences Renal Outcome in ADPKD
Cornec-Le Gall, E., Audrézet, M.-P., Chen, J.-M., Hourmant, M., Morin, M.-P., Perrichot, R., Charasse, C., Whebe, B., Renaudineau, E., Jousset, P., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070650 · Cited by 530
Self-citationKidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease
Chapman, A. B., Bost, J. E., Torres, V. E., Guay-Woodford, L., Bae, K. T., Landsittel, D., Li, J., King, B. F., Martin, D., Wetzel, L. H., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09500911 · Cited by 378
Cornec-Le Gall, E., Audrézet, M.-P., Rousseau, A., Hourmant, M., Renaudineau, E., Charasse, C., Morin, M.-P., Moal, M.-C., Dantal, J., Wehbe, B., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010016 · Cited by 359
Self-citationWhy kidneys fail in autosomal dominant polycystic kidney disease
Grantham, J. J., Mulamalla, S., & Swenson-Fields, K. I. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.109 · Cited by 287
Autosomal dominant polycystic kidney disease: the changing face of clinical management
Ong, A. C. M., Devuyst, O., Knebelmann, B., & Walz, G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60907-2 · Cited by 280
Self-citationGrantham, J. J., Chapman, A. B., & Torres, V. E. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00330705 · Cited by 278
Rare inherited kidney diseases: challenges, opportunities, and perspectives
Devuyst, O., Knoers, N. V. A. M., Remuzzi, G., & Schaefer, F. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60659-0 · Cited by 244
Self-citationSpithoven, E. M., Kramer, A., Meijer, E., Orskov, B., Wanner, C., Abad, J. M., Areste, N., Alonso de la Torre, R., Caskey, F., Couchoud, C., et al. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu017 · Cited by 242
Self-citationWatkins, P. B., Lewis, J. H., Kaplowitz, N., Alpers, D. H., Blais, J. D., Smotzer, D. M., Krasa, H., Ouyang, J., Torres, V. E., Czerwiec, F. S., et al. (2015) · Drug Safety · doi:10.1007/s40264-015-0327-3 · Cited by 194
Predictors of Autosomal Dominant Polycystic Kidney Disease Progression
Schrier, R. W., Brosnahan, G., Cadnapaphornchai, M. A., Chonchol, M., Friend, K., Gitomer, B., & Rossetti, S. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013111184 · Cited by 171
Torres, V. E., Higashihara, E., Devuyst, O., Chapman, A. B., Gansevoort, R. T., Grantham, J. J., Perrone, R. D., Ouyang, J., Blais, J. D., Czerwiec, F. S., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06300615 · Cited by 171
Self-citationStimulation by vasopressin of glycogen breakdown and gluconeogenesis in the perfused rat liver
Hems, D. A., & Whitton, P. D. (1973) · Biochemical Journal · doi:10.1042/bj1360705 · Cited by 150 · cited 1×
“V2 receptor blockade results in a slight compensatory increase in circulating arginine vasopressin [49], which in theory may stimulate hepatic glucose production via increased activation of V1a receptors [50].”
BackgroundKistler, A. D., Poster, D., Krauer, F., Weishaupt, D., Raina, S., Senn, O., Binet, I., Spanaus, K. S., Wuthrich, R. P., & Serra, A. L. (2008) · Kidney International · doi:10.1038/ki.2008.558 · Cited by 149
Irazabal, M. V., Torres, V. E., Hogan, M. C., Glockner, J. F., King, B. F., Ofstie, T. G., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2011) · Kidney International · doi:10.1038/ki.2011.119 · Cited by 139
Spithoven, E. M., Kramer, A., Meijer, E., Ørskov, B., Wanner, C., Caskey, F. J., Collart, F., Finne, P., Fogarty, D. G., Groothoff, J. W., et al. (2014) · Kidney International · doi:10.1038/ki.2014.120 · Cited by 130
Self-citationBhutani, H., Smith, V., Rahbari-Oskoui, F. F., Mittal, A., Grantham, J. J., Torres, V. E., Mrug, M. M., Bae, K. T., Wu, Z., Ge, Y., et al. (2015) · Kidney International · doi:10.1038/ki.2015.71 · Cited by 128
Chapter 10: Immunoglobulin A nephropathy
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.23 · Cited by 125
Comparison between siblings and twins supports a role for modifier genes in ADPKD
Persu, A., Duyme, M., Pirson, Y., Lens, X. M., Messiaen, T., Breuning, M. H., Chauveau, D., Lévy, M., Grünfeld, J., & Devuyst, O. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.66003.x · Cited by 118
Self-citationImaging for the prognosis of autosomal dominant polycystic kidney disease
Bae, K. T., & Grantham, J. J. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.214 · Cited by 92
Boertien, W. E., Meijer, E., de Jong, P. E., Bakker, S. J. L., Czerwiec, F. S., Struck, J., Oberdhan, D., Shoaf, S. E., Krasa, H. B., & Gansevoort, R. T. (2013) · Kidney International · doi:10.1038/ki.2013.285 · Cited by 91
Self-citationRuggenenti, P. L., Gaspari, F., Cannata, A. N., Carrara, F., Cella, C., Ferrari, S., Stucchi, N., Prandini, S., Ene‐Iordache, B., Diadei, O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032533 · Cited by 62
Spithoven, E. M., Meijer, E., Boertien, W. E., Sinkeler, S. J., Tent, H., de Jong, P. E., Navis, G. J., & Gansevoort, R. T. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.03.030 · Cited by 26
Self-citation
Cited by
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Autosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Reducing the costs of chronic kidney disease while delivering quality health care: a call to action
on behalf of the European Kidney Health Alliance, Vanholder, R., Annemans, L., Brown, E., Gansevoort, R., Gout-Zwart, J. J., Lameire, N., Morton, R. L., Oberbauer, R., Postma, M. J., et al. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.63 · Cited by 368
Self-citationA Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Chebib, F. T., Perrone, R. D., Chapman, A. B., Dahl, N. K., Harris, P. C., Mrug, M., Mustafa, R. A., Rastogi, A., Watnick, T., Yu, A. S. L., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018060590 · Cited by 257
Metadata
- Authors
- Gansevoort, R. T., Arici, M., Benzing, T., Birn, H., Capasso, G., Covic, A., Devuyst, O., Drechsler, C., Eckardt, K.-U., Emma, F., Knebelmann, B., Le Meur, Y., Massy, Z. A., Ong, A. C. M., Ortiz, A., Schaefer, F., Torra, R., Vanholder, R., Więcek, A., Zoccali, C., & Van Biesen, W.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-29
- Volume
- 31
- Issue
- 3
- Pages
- 337-348
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- OpenAlex
- W2269899460
- Cited by
- 255
- References
- 37
- FWCI
- 25.20
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.